Clear cell renal cell carcinoma (ccRCC, first-, second- and third-line) - metastatic castration-resistant prostate cancer (mCRPC, second-line post NHT) - urothelial carcinoma (UC) ICI naïve and ICI-experienced - non-clear cell renal (nccRCC, first-line) cell carcinoma - Colorectal cancer (CRC) - Hepatocellular cancer (HCC) - Non-small cell lung caner (NSCLC) - Head and Neck Squamous Cell Carcinoma (HNSCC)

• This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics … Recruitment ended
  2023-510061-10-00 3 2023-01-09

Showing 1–1 of 1 trials